Onglyza Drug Injury Lawyers
Onglyza (saxagliptin) is a popular type 2 diabetes medication that has been linked to an increased risk of pancreatitis, pancreatic cancer and congestive heart failure.
The Food & Drug Administration has recommended that the label on Onglyza be updated to warn against the risk of heart failure, a side effect that is not listed on the medication’s label.
If you or someone you love has suffered medical complications after taking Onglyza, you may be entitled to compensation for your pain and suffering and other damages.
Onglyza Side Effects
In April 2015, the FDA assembled a panel to assess a study conducted in 2013 that had evaluated the likelihood of heart failure among diabetes patients taking certain medications, including Onglyza. The FDA concluded that Onglyza, also known as saxagliptin, created an increased risk of heart attack and that the label on the drug should change. One panel member suggested withdrawing the drug from the market.
...27 percent of patients who were hospitalized for cardiac issues had taken Onglyza.
The study assessed by the FDA was the 2013 SAVOR Outcomes trial. During the trial, more than 16,000 diabetes patients who were hospitalized because of heart failure were evaluated. The results of the trial specified that 27 percent of patients who were hospitalized for cardiac issues had taken Onglyza.
Previous studies have found a link between Onglyza and pancreatic cancer. In 2011, risks for pancreatic cancer were added to the drug’s warnings and precautions after reports of patients developing acute pancreatitis were sent to the FDA.
In 2013, a study published in the Diabetes journal also revealed a link between pre-cancerous cells in the pancreas and DPP-4 inhibitors, which is the class of drugs Onglyza is cataloged under. The FDA announced in March 2013 that it was evaluating these findings.
Who is At Risk?
In 2014, sales for Onglyza reached more than $800 million, making it one of the most popular type 2 diabetes medications.
AstraZeneca and Bristol-Myers Squibb received approval from the FDA to manufacture the drug in 2008.
As a result of concerns about heart attacks and other adverse events, the FDA required more post-approval testing to determine any Onglyza side effects. The study performed was the SAVOR Outcomes trial.
Consumers who were prescribed the drug may be at risk of cardiovascular events that could lead to hospitalization and even death. One Onglyza lawsuit filed in 2015 alleges that a woman died after taking the drug for several years. After being prescribed the drug in 2010, she was diagnosed with heart failure. The woman was hospitalized twice in 2013 for heart failure, and died in October 2013.
Filing an Onglyza Lawsuit
Negligent drug manufacturers need to be held accountable for failing to warn the public about the risks associated with their drugs.
The team of experienced personal injury lawyers at Goldberg Finnegan are ready to help victims of Onglyza obtain the compensation they deserve.
Our attorneys represent diabetes patients on a contingency fee basis, which means we don’t get paid, unless we obtain compensation for you.